12.52
-0.20 (-1.57%)
| Penutupan Terdahulu | 12.72 |
| Buka | 12.74 |
| Jumlah Dagangan | 101,916 |
| Purata Dagangan (3B) | 287,222 |
| Modal Pasaran | 418,473,504 |
| Harga / Buku (P/B) | 1.61 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 23.31 |
| Aliran Tunai Operasi (OCF TTM) | -66.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.10 M |
| Pulangan Atas Aset (ROA TTM) | -31.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | MBX Biosciences, Inc. | Menaik | - |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 0.5 |
| Purata | 1.63 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.12% |
| % Dimiliki oleh Institusi | 106.84% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 44.00 (Guggenheim, 251.44%) | Beli |
| Median | 41.00 (227.48%) | |
| Rendah | 38.00 (JMP Securities, 203.51%) | Beli |
| Purata | 41.00 (227.48%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 6.27 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 10 Apr 2025 | 44.00 (251.44%) | Beli | 6.27 |
| JMP Securities | 10 Apr 2025 | 38.00 (203.51%) | Beli | 6.27 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Jun 2025 | Pengumuman | MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions |
| 20 May 2025 | Pengumuman | MBX Biosciences to Participate in June Investor Conferences |
| 12 May 2025 | Pengumuman | MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
| 22 Apr 2025 | Pengumuman | MBX Biosciences to Participate in Citizens and RBC May Investor Conferences |
| 07 Apr 2025 | Pengumuman | MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors |
| 26 Mar 2025 | Pengumuman | MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference |
| 17 Mar 2025 | Pengumuman | MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |